Use of selective PDE IV inhibitors to treat dry eye disorders

Details Use of selective PDE IV inhibitors to treat dry eye disorders Use of selective PDE IV inhibitors to treat dry eye disorders

2005-03-29

2005-03-29

Azpuru, Carlos A. (Department: 1615)

Drug, bio-affecting and body treating compositions

Topical body preparation containing solid synthetic organic...

Ophthalmic preparation

Reexamination Certificate

active

06872382

ABSTRACT:
Selective PDE-IV inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

REFERENCES:
patent: 3991759 (1976-11-01), Urquhart
patent: 4131651 (1978-12-01), Shah et al.
patent: 4370325 (1983-01-01), Packman
patent: 4409205 (1983-10-01), Shively
patent: 4744980 (1988-05-01), Holly
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 4804539 (1989-02-01), Guo et al.
patent: 4818537 (1989-04-01), Guo
patent: 4883658 (1989-11-01), Holly
patent: 4914088 (1990-04-01), Glonek et al.
patent: 4956348 (1990-09-01), Gilbard et al.
patent: 4966773 (1990-10-01), Gressel et al.
patent: 4975428 (1990-12-01), Shell
patent: 5036046 (1991-07-01), Neufeld et al.
patent: 5041434 (1991-08-01), Lubkin
patent: 5075104 (1991-12-01), Gressel et al.
patent: 5174988 (1992-12-01), Mautone et al.
patent: 5278151 (1994-01-01), Korb et al.
patent: 5290572 (1994-03-01), MacKeen
patent: 5294607 (1994-03-01), Glonek et al.
patent: 5371108 (1994-12-01), Korb et al.
patent: 5393788 (1995-02-01), Bender et al.
patent: 5403841 (1995-04-01), Lang et al.
patent: 5449686 (1995-09-01), Christensen, IV et al.
patent: 5491147 (1996-02-01), Boyd et al.
patent: 5578586 (1996-11-01), Glonek et al.
patent: 5605914 (1997-02-01), Muller
patent: 5620921 (1997-04-01), Sullivan
patent: 5677335 (1997-10-01), Robertson et al.
patent: 5696166 (1997-12-01), Yanni et al.
patent: 5712298 (1998-01-01), Amschler
patent: 5800807 (1998-09-01), Hu et al.
patent: 5958912 (1999-09-01), Sullivan
patent: 6071904 (2000-06-01), Ali et al.
patent: 9474907 (1994-07-01), None
patent: 0 738 715 (1998-06-01), None
patent: WO 9200968 (1992-01-01), None
patent: WO 9501338 (1995-01-01), None
patent: WO 9509836 (1995-04-01), None
patent: WO 9527692 (1995-10-01), None
patent: WO 9531211 (1995-11-01), None
patent: WO 9535283 (1995-12-01), None
patent: WO 9535284 (1995-12-01), None
patent: WO 9600218 (1996-01-01), None
patent: WO 9601825 (1996-01-01), None
patent: WO 9632105 (1996-10-01), None
patent: WO 9600215 (1996-11-01), None
patent: WO 9636595 (1996-11-01), None
patent: WO 9950270 (1999-10-01), None
patent: WO 0003705 (2000-01-01), None
patent: WO 0043000 (2000-07-01), None
patent: WO 0061168 (2000-10-01), None
patent: WO 0064863 (2000-11-01), None
patent: WO03/03749 (2003-05-01), None
patent: WO 03099278 (2003-12-01), None
patent: WO 03099334 (2003-12-01), None
Ballestas et al., “Elevation of Cyclic AMP Levels in Astrocytes Antagonizes Cytokine-Induced Adhesion Molecule Expression,”J. of Neurochemistry,vol. 69(4), pp. 1438-1448 (1997).
Blease et al., “Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4,”British J. of Pharmacology,vol. 124, pp. 229-237 (1998).
Bode et al., “Distinct Profiles of Phosphodiesterase Isozymes in Cultured Cells Derived from Nonpigmented and Pigmented Ocular Ciliary Epithelium,” vol. 267 (3), pp. 1286-1291 (1993).
Bruynzeel et al., “Pentoxifylline Inhibits Human T-cell Adhesion to Dermal Endothelial Cells,”Arch. Dermatol Res.,pp. 189-193 (1997).
Corey et al., “Total Synthesis and Biological Activity of Lactacystin, Omuralide and Analogs,”Chem. Pharm. Bull.,vol. 47(1), pp. 1-10 (1999).
Driessens et al., “Activation of G-Proteins with AIF4Induces LFA-1-Mediated Adhesion of T-Cell Hybridoma Cells to ICAM-1 by Signal Pathways that Differ from Phorbol Ester and Manganese-Induced Adhesion,”Experimental Cell Research,vol. 231, pp. 242-250 (1997).
Gilbard et al., “Stimulation of Tear Secretion by Topical Agents,”Investigative Ophthalmology&Vis. Science,vol. 31(7), pp. 1381-1388 (1990).
Hayashi et al., “Butein (3,4,2′,4′-tetrahydroxychalcone) ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis (3),”European J. of Pharmacology,vol. 316, pp. 297-306 (1996).
Knorr et al., “The Lymphocyte Function-associated Antigen 1 I Domain is a Transient Binding Module for Intercellular Adhesion Molecule (ICAM)-1 and ICAM-3 in Hydrodynamic Flow,”J. Exp. Medicine,vol. 186(5), pp. 719-730 (1997).
Lemp et al., “Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes,”CLAO Journal,vol. 21(4), pp. 221-231 (1995).
Liefner et al., “Concentration-dependent effects of pentoxifylline on mirgration and myelin phagocytosis by macrophages,”J. of Neuroimmunology,vol. 89, pp. 97-103 (1998).
McCulley et al., “Tear Film Structure and Dry Eye,”Contactologia,vol. 20, pp. 145-149 (1998).
Marsh et al., “Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjogren Syndrome,”Ophthalmology,vol. 106(4), pp. 811-816 (1999).
Modur et al., “Endothelial Cell Inflammatory Responses to Tumor Necrosis Factor,”J. of Biological Chemistry,vol. 271(22), pp. 13094-13102 (1996).
Morandini et al., “Action of cAMP in expression and release of adhesion molecules in human endothelial cells,”American J. of Physiology,vol. 270(3 Pt 2), pp. H807-H816 (1996).
Newsholme et al., “cAMP-Specific Phosphodiesterase Inhibitor, Rolipram, Reduces Eosinophil Infiltration Evoked by Leukotrienes or by Histamine in Guinea Pig Conjunctiva,”Inflammation,vol. 17(1), pp. 25-31 (1993).
Poggi et al., “Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by the use of cholera or pertussis toxin,”Eur. J. Immunology,vol. 26, pp. 967-975 (1996).
Rieckmann et al., “Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis,”J. of Neuroimmunology,vol. 64, pp. 193-200 (1996).
Shafren et al., “Coxackievirus A21 Binds to Decay-Accelerating Factor but Requires Intercellular Adhesion Molecule 1 for Cell Entry,”J. of Virology,vol. 71 (6), pp. 4736-4743 (1997).
Shine et al., “Keratoconjunctivitis Sicca Associated with Meibornian Secretion Polar Lipid Abnormality,”Arch. Ophthalmol.vol. 116, pp. 849-852 (1998).
Soucy et al., “A Novel and Efficient Synthesis of a Highly Active Analogue of clasto-Lactacystin β-Lactone,” J. Am. Chem. Soc, vol. 121, pp. 9967-9976 (1999).
Tauber et al., “A Dose-Ranging Clinical Trial to Assess the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients with Keratoconjunctivitis Sicca,” Lacrimal Gland, Tear Film and Dry Eye Syndromes 2, edited by Sullivan et al., Plenum Press, New York, pp. 969-972 (1998).

Affiliated with

Also associated with

Rating

Use of selective PDE IV inhibitors to treat dry eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of selective PDE IV inhibitors to treat dry eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of selective PDE IV inhibitors to treat dry eye disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3455131